CMN Weekly (30 May 2025) - Your Weekly CRISPR...
CMN Weekly
May. 30, 2025
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Grit Biotechnology
Company Type: Therapeutic development
Main focus: Developing cell therapies to advance cancer immunotherapies
Company stage: Clinical
Diseases: Haematological and solid cancers
Genome-editing tool: CRISPR-Cas9
Funding stage: Series B
Location: Shanghai, Shanghai, China
Website: www.grit-bio.com/sy
Pipeline: www.grit-bio.com/sy
Partners:
Grit Biotechnology is a clinical-stage biotechnology company focused on the development of gene-edited cell therapies to advance immunotherapies, specifically tumour-infiltrating lymphocyte (TIL) therapy, in treating various cancers. The company has established five proprietary platforms: StemTexp®, StaViral®, ImmuT Finder®, KOReTILTM, and TST HunderTM, which aim to advance different areas of cell therapy development. The company utilises CRISPR-Cas9 machinery in engineering TIL cells to enhance functionality and efficacy.
